查詢結果分析
來源資料
相關文獻
- Outcomes of Mechanically Ventilated Non-Small Cell Lung Cancer Patients Receiving Tyrosine Kinase Inhibitors in Intensive Care Units
- 加護病房護理人員更換呼吸器管路過程標準化
- 外科加護病房呼吸器管路更換頻率與其肺炎相關感染率之比較
- 縮短兒科加護病房呼吸器管路裝置時間
- 不同鼻胃管灌食方法對重症呼吸器使用病人照護成效之探討
- Ventilator Related Nosocomial Infection in MICU Patients
- 某內科加護病房搬遷前後呼吸器相關肺炎之比較分析
- 呼吸治療技術與醫院空氣品質
- 抗血管新生治療於非小細胞肺癌之應用
- 組合式感染控制措施(Bundle Intervention)降低呼吸器相關肺炎感染發生:某區域醫院內科加護病房推行經驗
頁籤選單縮合
題名 | Outcomes of Mechanically Ventilated Non-Small Cell Lung Cancer Patients Receiving Tyrosine Kinase Inhibitors in Intensive Care Units=非小細胞肺癌病人在加護病房接受標靶藥物的成果 |
---|---|
作者 | 王劭瑜; 張志豪; 胡漢忠; 高國晉; 馮博皓; 徐稟智; 邱立忠; 洪禎佑; 陳濘宏; 黃崇旂; 楊政達; 蔡熒煌; Wang, Shao-yu; Chang, Chih-hao; Hu, Hang-chung; Kao, Kuo-chin; Feng, Po-hao; Hsu, Ping-chih; Chiu, Li-chung; Hung, Chen-yiu; Chen, Ning-hung; Huang, Chung-chi; Yang, Cheng-ta; Tsai, Ying-huang; |
期刊 | 胸腔醫學 |
出版日期 | 20150600 |
卷期 | 30:3 2015.06[民104.06] |
頁次 | 頁125-133 |
分類號 | 415.468 |
語文 | eng |
關鍵詞 | 非小細胞肺癌; 酪胺酸激酶抑制劑; 呼吸器; 加護病房; Non-small cell lung cancer; Tyrosine kinase inhibitors; Mechanical ventilation; Intensive care units; |
中文摘要 | 前言:標靶藥物—表皮生長因子接受器- 酪胺酸激酶抑制劑(epidermal growth factor receptor-tyrosine kinase inhibitors, EGFR-TKIs)在非小細胞肺癌併呼吸器支持的病人上,其臨床療效尚不明確。本篇研究旨在探討呼吸器支持下的非小細胞肺癌病人接受標靶藥物治療的成果。 方法:自2004 年1 月1 號至2010 年7 月1 號加護病房中的回溯性分析。 結果:91 位非小細胞肺癌併呼吸器支持的病人使用標靶藥物EGFR-TKIs,33 人(36%)成功脫離呼吸器,其中有13 人(14%)對標靶治療有反應。年齡、性別、日常體能狀態(performance status)、APACHE II score、腫瘤分型和期別不影響呼吸器的脫離。進入加護病房前腫瘤在穩定狀態(controlled disease)或在加護病房中對標靶藥物治療有反應的病人有較高的比例成功脫離呼吸器(分別為39% 和52%)。 結論:原腫瘤在穩定狀態或對標靶治療有反應的非小細胞肺癌患者,即使在接受呼吸器支持下,仍值得更積極的治療。 |
英文摘要 | Background: The clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) of critically ill non-small cell lung cancer (NSCLC) patients has not been well addressed. The purpose of this study was to investigate the outcome of mechanically-ventilated (MV) NSCLC patients under EGFR-TKI treatment. Methods: A retrospective study of NSCLC patients in medical intensive care units (ICUs) between January 1, 2004 and July 1, 2010. Results: Thirty-three (36%) of the 91 NSCLC patients with MV taking EGFR-TKIs were successfully weaned from MV, including 13 (14%) who were responsive to EGFR-TKI treatment. Age, gender, performance status, Acute Physiology and Chronic Health Evaluation II score, cancer cell type and stage did not affect the outcome of MV weaning. Patients with controlled disease before ICU admission and those with EGFR-TKI response in the ICU achieved a significantly higher rate of successful weaning (39% and 52%, respectively). Conclusions: NSCLC patients with controlled disease or EGFR-TKI response may need more aggressive management, even if they are under MV. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。